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Abstract 
Neurological deterioration in Parkinson’s disease (PD) and resulting motor dysfunction arises from Lewy body 
formation and dopaminergic neuronal death in the substantia nigra. Two factors contributing to PD-related apoptosis 
and subsequent motor dysfunction involve improper cellular metabolism of reactive oxygen species (ROS) and 
impaired mitochondrial functionality. The co-factor Nicotinamide Adenine Dinucleotide (NAD+), reduction of which 
has been implicated in the development of neurodegenerative disease, is a critical player in maintaining cellular redox 
metabolism and mitochondrial function. We present a case study of a PD patient who has become near asymptomatic 
through the use of intravenous (I.V.) NAD+. This report documents the patient’s initial symptom changes while 
receiving I.V. NAD+ over the course of eight treatment days, with two non-treatment days in between. The treatment 
entailed 1500 mg. I.V. NAD+ on day one, 1000 mg. I.V. NAD+ on day two, and 750 mg. I.V. NAD+ on day three. 
Symptoms were documented by medical staff for the next two days of non-treatment. Following this, 750 mg. I.V. NAD+ 
was administered on treatment days four and five, 500 mg. I.V. NAD+ on treatment days six and seven, and 750 mg. 
I.V. NAD+ on treatment day eight. Over the course of treatment, the patient’s hand tremors decreased to a mild level, 
permitting coordinated use of a pen and utensils. Hand tremors were absent on days one and six. Visual hallucinations 
were absent on days two through seven. To maintain tremors at a tolerable level, aftercare involved I.V. NAD+ every 
four to six weeks, with a daily regimen of 300 mg/ml NAD+ nasal spray. Moreover, the patient discontinued PD-related 
medication, thereby preventing visual hallucination side effects. Although more research on NAD+ in clinical use is 
needed, the evidence obtained from these symptom improvements indicates NAD+ as having the potential for clinical 
use in at least a subset of PD sufferers. 
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Introduction 
Recognized as the world’s second most common adult-onset neurodegenerative disease, Parkinson’s disease 
(PD) is a progressively debilitating disorder characterized by disturbances in motor functionality, including resting 
tremors, bradykinesia and muscular rigidity [1]. Side effects of commonly prescribed anti-PD treatment may also result 
in medication-induced visual hallucinations and paranoid delusions [2]. 
It is understood that neurological deterioration in PD results from the formation of Lewy bodies and the 
selective death of dopaminergic neurons within the substantia nigra. Increasing evidence asserts the interplay of 
improper cellular metabolism of reactive oxygen species (ROS), coincided with impaired mitochondrial function, as 
two interwoven factors contributing to PD-related apoptosis and subsequent motor dysfunction [3,4]. The co-factor 
nicotinamide adenine dinucleotide (NAD+) is a critical player in healthy cellular redox metabolism and mitochondrial energy 
production [5,6]. In fact, a decrease in available NAD+ has been implicated in the development of neurodegenerative disease 
[7]. Thus, it may be worth considering the potential effects flowing from a dysregulation of this central molecule in 
understanding the metabolic dysfunctions driving the development of PD and subsequent treatment. 
Case Report 
We report a case of a patient diagnosed with PD and documents his symptom changes over eight days of 
intravenously administered supplemental NAD+ therapy. An 80-year-old man with a fourteen-year history of PD, with 
no other documented health or psychiatric illnesses, sought treatment at an outpatient clinic specializing in intravenous 
NAD+ therapy. He was observed over a period of eight treatment days, with a break of two non-treatment days in 
between to accommodate a prior engagement. 
Before his arrival, his symptoms included severe bilateral hand tremors, inability to hold utensils or sign his 
name, peripheral hallucinations, decreased social interaction, and overall compromised quality of life. The patient 
utilized 1.5 mg per day of Mirapex to treat his symptoms at the time of intake. The following observations were 
documented by medical staff as well as by the patient himself.  
Prior to infusion on day one, the patient reported experiencing severe bilateral hand tremors and visual 
hallucinations. Approximately two hours into his first NAD+ infusion, his tremors became unnoticeable, remaining so 
throughout the rest of that day’s treatment, and only returning mildly in the evening. Additionally, the patient was 
finally able to hold utensils comfortably. On treatment day two, some hand tremors were present throughout the day, 
yet were significantly improved compared to time of arrival. There was a newly marked absence of visual hallucinations. 
On treatment day three, he experienced minor hand tremors throughout the day. 
The following two days were days of non-treatment. On the first day of non-treatment, the patient reported a 
mild shaking of his right thumb upon waking, and slight tremors in both hands as the day progressed. By the next day 
of non-treatment, the patient reported that his hand tremors increased somewhat with movement, yet not while at rest, 
as the day progressed. 
Commencing day four of treatment, the patient reported slight tremors upon waking which remained mild 
throughout the day. On treatment day five, while he still experienced mild bilateral tremors throughout the day, it was 
observed that he could write legibly. On treatment day six, he reported slight shaking in both thumbs only upon waking, 
which later disappeared throughout treatment. On treatment day seven, he reported no feeling of shakiness in either hand 
upon waking, although shakiness returned slightly as the day progressed. Upon waking the next morning prior to the eighth 
day of infusion, the patient only reported some peripheral hallucinations. His hallucinations disappeared over the course 
of this final, eighth NAD+ infusion. He was observed to have slight hand tremors, which remained throughout this 
treatment day. By the end of his treatment program, he had received a total of 6500 mg of I.V. NAD+ (Table 1). 
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Table 1: Summary of Treatment Days and Corresponding PD Symptoms 
Day 
Amount of NAD+ 
Delivered (mg) 
PD Symptoms and Symptom Changes 
Baseline 0 
• Severe bilateral hand tremors 
• Inability to hold utensils 
• Inability to sign name and write legibly 
• Visual hallucinations 
• Decreased social interactions 
Day 1 
Treatment Day 1 
1,500 
• Hand tremors absent, returning slightly into 
evening 
• Ability to hold utensils* 
Day 2 
Treatment Day 2 
1,000 
• Mild hand tremors present 
• Visual hallucinations disappear 
Day 3 
Treatment Day 3 
750 • Mild hand tremors present 
Day 4 
Non-treatment 
0 • Mild hand tremors present 
Day 5 
Non-treatment 
0 • Mild hand tremors present 
Day 6 
Treatment Day 4 
750 • Mild hand tremors present 
Day 7 
Treatment Day 5 
750 
• Mild hand tremors present 
• Ability to write legibly* 
Day 8 
Treatment Day 6 
500 • Hand tremors absent 
Day 9 
Treatment Day 7 
500 • Mild Hand tremors present 
Day 10 
Treatment Day 8 
750 
• Peripheral hallucinations present in morning, but 
later disappear 
• Hand tremors present with movement only 
*This symptom change began on this day and follows into the patient’s current state. 
For follow-up PD maintenance, the patient regularly receives 1,000 mg of intravenous NAD+ boosters, 
approximately every 4-6 weeks. He also maintains his symptoms with a 300 mg/ml NAD+ nasal spray (0.1 ml per spray), 
twice in each nostril daily. This regimen continues to maintain his tremors at a tolerable, mild rate, allowing him significantly 
greater participation in daily activities (e.g. he has begun riding a bike again). In addition, as the patient’s neurological  
symptoms have been significantly improved, he has been able to discontinue his PD-related medication. Using NAD+ 
therapy alone has also enabled him to live without visual hallucinations. In all, he reports his quality of life as far more 
manageable and enjoyable, allowing him the ability to participate in many activities previously rendered impossible. 
The reduction in PD symptoms this patient experienced during initial treatment, including the eventual 
discontinuation of anti-PD medication, lends significant anecdotal support for the use of NAD+ as a potentially useful 
treatment for at least a subset of Parkinson’s disease patients. Although the biochemical processes involved in PD 
pathogenesis are complex and varying between cases, the association between increased oxidative damage and reduced 
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NAD+ availability in the pathobiochemistry of neurodegenerative disease provide at least some rationale for the marked 
symptom reduction in this case [7,8]. Additionally, as prior research suggests, increasing the availability of NAD+ to 
dopaminergic neurons in the nigrostriatal tracts may have the potential to promote healthy mitochondrial function and 
DNA repair. Moreover, in a murine model, NAD+ supplementation has demonstrated neuronal restoration following 
the induction of neurodegeneration [9,10]. Furthermore, one recent study has directly linked NAD+ precursor 
administration to preventing dopaminergic neuronal loss in PD patient derived induced pluripotent stem cells [11]. 
Overall, our current study supports the notion that NAD+ supplementation may be increasing cellular resilience to 
ongoing dopaminergic neuronal loss in this particular PD sufferer. 
Although the evidence obtained from observations reported for this single individual does not claim that NAD+ 
targets disease pathogenesis, the significant clinical improvements indicate that NAD+ therapy can alleviate symptoms 
in at least a subset of PD sufferers. These extraordinary observations warrant further clinical investigation of NAD+ and 
its potential to modulate key cellular processes impaired in neurodegenerative diseases such as PD. 
While further research will be needed, these observations implicate that NAD+ supplementation can have 
therapeutic value for at least symptomatic treatment in this neurodegenerative disease. 
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